[Ip-health] Infojustice Roundup - March 2, 2015

Michael Palmedo mpalmedo at wcl.american.edu
Mon Mar 2 09:17:58 PST 2015

Infojustice Roundup 




LDC Members’ Entitlement to and Need for a Further Extension of Their Pharmaceutical Transition Period


[Brook Baker] LDCs Members have submitted a duly motivated request for an unconditional extension of the 2002-2016 pharmaceutical transition period (covering patents and data) and for relief from the requirements of TRIPS Article 70.8 and 70.9 (mailbox and marketing exclusivity provisions).  This expert analysis confirm LDCs’ need and entitlement to the requested extension.​ Click here for more. <http://infojustice.org/archives/33969> 


See also:  

·         K.M. Gopakumar for the South-North Development Monitor. WTO - LDC request for extension of transition period on pharmaceuticals. (Link <http://lists.keionline.org/pipermail/ip-health_lists.keionline.org/2015-February/004896.html> )

·         Ellen t'Hoen for IP-Watch. Why The Request By Least Developed Countries For An Extension Of The Transitional Period For Granting And Enforcing Medicines Patents Needs To Be Supported. (Link <http://www.ip-watch.org/2015/02/27/why-the-request-by-least-developed-countries-for-an-extension-of-the-transitional-period-for-granting-and-enforcing-medicines-patents-needs-to-be-supported/> )




The Medicines Patent Pool Signs Licensing Agreement with MSD for Paediatric Formulations of Raltegravir


[Medicines Patent Pool]  The Medicines Patent Pool (MPP) announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older. With the new licence, generic manufacturers and other companies based anywhere in the world can develop, manufacture and sell low cost, paediatric versions of raltegravir in countries with the highest burden of disease, where 98 percent of children with HIV in the developing world live. Click here for more. <http://infojustice.org/archives/33959> 




Yale Report: Millions of People with Hepatitis C Blocked from Obtaining Treatment in Low-and Middle-Income Countries


[Yale Global Health Partnership press release] Just last week, worldwide leaders came together in Geneva, Switzerland at the World Health Organization to begin to develop a five-year strategy to combat Hepatitis C. The disease, which affects 185 million people worldwide – five times as many people as HIV, predominantly in low-and middle-income countries – has been called a silent epidemic. Now, a new report by Yale’s Global Health Partnership (GHJP), the Treatment Action Group (TAG) and the Initiative for Medicines, Access and Knowledge (I-MAK) warns that global efforts to extend treatment to millions is in peril unless key obstacles to access are confronted immediately…  strategies used with other diseases, particularly HIV/AIDS, to extend treatments to millions who need it has largely depended on getting less expensive, generic versions of these drugs on the market, by pressuring companies to allow other manufacturers to produce their drugs. Click here for more. <http://infojustice.org/archives/33986>  



More information about the Ip-health mailing list